Welcome to our dedicated page for Retractable Tech SEC filings (Ticker: RVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Retractable Technologies, Inc. (RVP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Retractable’s filings, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports, describe its business of manufacturing and marketing VanishPoint®, EasyPoint®, and Patient Safe® safety medical products, as well as key financial and operational details.
In its periodic reports, Retractable discusses net sales, operating income or loss, domestic and international revenue mix, and the influence of product mix between VanishPoint® syringes and EasyPoint® needles on average selling prices and margins. The filings also address the material impact of tariffs on needles, syringes, and other products imported from China, and explain how these costs are reflected in cost of manufactured product. Disclosures describe the company’s efforts to increase U.S.-based manufacturing, adapt equipment for domestic production, and adjust its workforce in response to tariff pressures.
Form 8-K current reports for RVP document material events such as quarterly and annual results announcements, preferred stock dividend declarations for Series II Class B and Series III Class B Convertible Preferred Stock, workforce reductions, and product-related recognitions. These filings confirm that Retractable’s common stock is registered on NYSE American under the symbol RVP and that the company is incorporated in Texas.
On Stock Titan, users can review these SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as discussions of tariffs, product mix, liquidity considerations, and risk factors related to patent protection, supplier relationships, foreign trade risk, access to markets, production costs, and competition from larger safety device providers. The platform also surfaces updates in near real time as new filings are posted to EDGAR, helping users quickly see changes in Retractable’s reported results, capital structure, or material events.
By combining the full text of RVP’s SEC filings with AI-generated explanations, this page is intended to make it easier to understand how Retractable’s safety medical device business, financial performance, and risk disclosures are presented in its official regulatory documents.
Retractable Technologies, Inc. reported 2025 results showing revenue growth but continued operating losses, and announced dividends on its Series II and III Class B preferred stock. Revenues rose 15.8% to about $38.3 million from $33.0 million, driven by higher VanishPoint® and EasyPoint® needle sales, especially internationally where revenue increased 64.0%.
Total operating expenses were $21.2 million, resulting in a 2025 loss from operations of $21.2 million, similar to the prior year. Cash decreased by $1.6 million to $2.6 million at year-end, while the company held $34.4 million in debt and equity securities. Management notes that 62.6% of products came from China and that a 120% tariff rate on many imported syringe and needle products, along with about $1.8 million of tariff expense in 2025, is expected to continue having a material impact.
The board declared dividends of $39,050.00 on Series II Class B and $18,561.25 on Series III Class B Convertible Preferred Stock for the period January 1 through March 31, 2026, at $1.00 per share per year. These dividends will be paid on April 20, 2026 to holders of record on April 10, 2026.
Retractable Technologies, Inc. reported 2025 net sales of $38.3M, up 15.8% from 2024, but still posted a net loss of $12.6M or $0.43 per share. Gross margin barely broke even as heavy tariff costs and manufacturing expenses offset higher volumes.
About 62.6% of products were sourced from China in 2025, and tariffs on Chinese syringes and needles reached a combined rate of roughly 120% by early 2026, materially pressuring results. Tariff expense was about $1.8M in 2025, driving the company to accelerate a shift toward domestic production and adapt equipment for 0.5 mL syringes.
International revenue rose 64.0% with unit volume up 164.7%, helped by EasyPoint needles, though discounted pricing reduced margins. The company also holds $34.4M in marketable securities, or 24.1% of total assets, creating earnings volatility from investment gains and losses. Stockholders’ equity was $74.4M at year-end versus a market capitalization of $23.1M, and management highlighted concern that the share price does not reflect underlying value.
Retractable Technologies, Inc. is asking shareholders to vote at its virtual 2026 annual meeting on May 8, 2026, primarily on the election of three Class 2 directors: Thomas J. Shaw, Walter O. Bigby, Jr., and John W. Fort III, each to serve until the 2028 meeting.
The meeting will be held online at 10:00 a.m. Central time, with voting available by internet, phone, mail, or during the webcast for holders of common stock as of March 9, 2026, when 29,937,159 shares were outstanding. The board recommends voting “For All” director nominees.
Governance details show a six-member classified board with a majority of independent directors and combined Chairman/CEO roles held by founder Thomas J. Shaw. As of March 9, 2026, Mr. Shaw beneficially owned 16,662,822 common shares, or 55.7% of the class, giving him effective control. He also receives a 5% royalty on licensed product sales, totaling $3,154,263 in 2025.
Executive pay is heavily salary-based. In 2025, CEO compensation totaled $1,222,045, General Counsel $410,500, and CFO $309,992. The disclosed pay ratio shows median employee compensation of $37,458 versus CEO pay, a ratio of 1:32.34. Baker Tilly US, LLP has been selected again as independent auditor, with 2025 audit fees of $503,475.
Retractable Technologies, Inc. disclosed that on December 30, 2025 it issued a press release announcing the declaration of a dividend for holders of its Series II and Series III Class B Convertible Preferred Stock. The announcement applies only to these preferred stock classes and does not mention the common stock. The details of the dividend itself are contained in the attached press release identified as Exhibit 99.
Retractable Technologies (RVP) reported an insider share purchase by its President and CEO, who is also a director and 10% owner. On 11/14/2025, he bought 5,731 shares of common stock at a weighted average price of $0.772 per share, reported as an open-market purchase. Following this transaction, he directly owns 15,831,222 shares of common stock and indirectly holds 831,600 shares through voting or investment control arrangements, including 500,000 shares held as trustee for a family member. The transaction was executed under a Rule 10b5-1 trading plan that was adopted on August 22, 2024.
Retractable Technologies, Inc. (RVP) filed a Form 8‑K announcing it issued two press releases. One release reports results for the periods ended September 30, 2025, and the other announces the Company’s receipt of an Innovative Technology designation from Vizient®.
The earnings release is furnished as Exhibit 99.1, and the Vizient designation release is furnished as Exhibit 99.2. RVP’s common stock trades on the NYSE American under the symbol RVP.
Retractable Technologies (RVP) filed its Q3 2025 10‑Q, reporting sales of $10,085,723 and net income of $371,047 (EPS $0.01). Gross profit was $1.69M with a loss from operations of $3.65M, offset by Other income – TIA of $1.52M and an unrealized gain on investments of $2.38M.
For the first nine months, sales were $28,826,629 with a net loss of $(10,217,140). Cash was $3.44M and investments at fair value were $30.50M; other long‑term liabilities related to the TIA were $59.40M. Three significant customers represented 57.3% of Q3 net sales.
The company highlighted tariff headwinds on China‑sourced syringes and needles, with prevailing rates at 130%. Tariff expense was $172K in Q3 and $2.3M year‑to‑date. Management is shifting more production to its U.S. facility, which raises payroll by about $825K annually but is expected to reduce tariff exposure. Inventory write‑downs were about $1.2M year‑to‑date. Shares outstanding were 29,937,159 as of November 3, 2025.
Retractable Technologies (RVP) reported an insider transaction by its President and CEO, a Director and 10% Owner. On 11/11/2025, the insider purchased 100 shares of common stock at a weighted average price of $0.8111 (Code P).
Following the transaction, beneficial ownership was 15,825,491 shares direct and 831,600 shares indirect. The filing notes that the insider has investment power over 500,000 shares as Trustee for a family member and voting control over the remainder pursuant to a voting agreement. A Rule 10b5-1 plan was adopted on August 22, 2024.
Retractable Technologies (RVP) reported an insider purchase by its President & CEO, Director, and 10% Owner, Mr. Shaw. On 11/05/2025, he acquired 7,500 shares of common stock at a weighted average price of $0.826 (transaction code P).
Following this trade, Mr. Shaw beneficially owns 15,825,391 shares directly and 831,600 shares indirectly. The indirect holdings include 500,000 shares over which he has investment power as Trustee for a family member, with voting control over the remainder pursuant to a voting agreement.
The filing notes a Rule 10b5-1 trading plan, with a date of adoption of August 22, 2024.
Retractable Technologies (RVP) disclosed an insider share purchase by President & CEO, Director, and 10% Owner Thomas J. Shaw. On 10/30/2025, he reported buying 15,000 shares of common stock (transaction code P) at a $0.861 weighted average price.
Following the transaction, Mr. Shaw beneficially owns 15,817,891 shares directly and 831,600 shares indirectly, noted as “Voting or Investment Control.” The filing explains he has investment power over 500,000 shares as trustee for a family member and voting control over the remainder under a voting agreement. The transaction was made under a Rule 10b5-1 plan adopted on August 22, 2024.